In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 30, No. 15_suppl ( 2012-05-20), p. 8566-8566
Abstract:
8566 Background: Checkpoint blockade through CTLA4 with ipilimumab has for the first time improved survival in patients with advanced melanoma. Immune-mediated toxicity and increase in humoral and T-cell anti-NY-ESO-1 immune responses after treatment are both linked with benefit. However there is currently no broadly relevant, immunological biomarker for predicting outcome prior to initiation of therapy. Methods: Using a novel immunological assay developed by Serametrix Corporation we analysed the presence of antibodies to a proprietary panel of tumour associated antigens (TAAs) in 34 patients with advanced melanoma, given ipilimumab at 3mg/kg as second or subsequent line of treatment. Results: 34 patients were consented and analysed, 22 females, 13 males. With a median age of 63 years median overall survival was 24 weeks; 6/34 patients had an objective response to ipilimumab (17.6%, median survival not reached). Antibody (AB) responses were tested against the panel of 26 TAAs. This panel includes BRAF, Cancer/Testis and other described or novel TAAs. We observed a wide range in the incidence and levels of antibody response. 12 patients had no detectable immunity, 6 an AB response to a single antigen, 5 AB response to 2, and 11 patients to 3 or more TAA. Five patients had either pre-existing anti-BRAF antibodies or developed these after CTLA4-blockade. Survival was significantly longer in those patients with pre-existing antibodies to 2 or more TAA, compared to those with 0 or 1 specificities (median survival 39.4 vs 16.4 weeks p=0.02). Conclusions: Patients with advanced melanoma had variable levels of humoral immunity to a large number of TAA, including to BRAF. The presence of antibody response to 2 or more TAA correlated with longer survival following treatment with ipilimumab and appears to provide a biomarker for identifying those patients that are most likely to respond to checkpoint blockade with ipilimumab.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2012.30.15_suppl.8566
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2012
detail.hit.zdb_id:
2005181-5
